Case Report

Neuroblastoma presenting as hip pain and skull prominence in a child

Hunter R. Hewitt, BS\textsuperscript{a,1}, Kimberly L. Fugok, DO\textsuperscript{a,1}, Marna Rayl Greenberg, DO, MPH\textsuperscript{a,1,*}, Andrew C. Miller, DO\textsuperscript{a,1}, Mini G. Abraham, MD\textsuperscript{c,1}, Richard J. Mazzaccaro, MD, PhD\textsuperscript{b,1}

\textsuperscript{a} Departments of Emergency and Hospital Medicine, CC & I-78 2545 Schoenersville Rd, Muhlenberg Campus LVH, 5th floor EM Residency Suite, Allentown, PA 18103
\textsuperscript{b} Department of Pediatrics, CC & I-78, Allentown, PA 18103
\textsuperscript{c} Department of Anatomic Pathology, CC & I-78, Allentown, PA 18103

\section*{A R T I C L E   I N F O}

Article history:
Received 4 August 2019
Revised 4 September 2019
Accepted 7 September 2019
Available online 26 September 2019

Keywords:
Neuroblastoma
Pediatric

\section*{A B S T R A C T}

Neuroblastoma is a common cancer in children especially those under 5-years old, however they can have varied presentations that may make diagnosis difficult. Neuroblastoma is not usually high on a clinician’s differential for a child’s gait dysfunction. We describe a case of a 6-year-old female who presented to the Emergency Department for new onset right hip pain. She had associated gait disturbance and pain with ambulation as well as a new lump on her right parietal skull. An MRI of the brain, lumbar spine, and pelvis revealed the diagnosis of a left adrenal neuroblastoma that had metastasized to the femur, the lumbar spine, and the skull. This case shows the importance of early suspicion of malignancy in a patient with seemingly disparate symptoms to ensure early intervention.

© 2019 The Authors. Published by Elsevier Inc. on behalf of University of Washington.

This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

\section*{Case presentation}

A previously healthy 6-year-old presented to the Emergency Department with a 6-day complaint of right hip pain. She had begun to walk on her toes with a limp. She also reported a 4-day headache that improved with sleep and didn’t improve with nonsteroidal anti-inflammatory medication. Her family reported an atraumatic “bump” on her head for 2 weeks. Other than her complaint of headache she had no neurological complaint or finding on initial evaluation.

The patient was febrile (100.8°F) with a hard deformity on the right parietal skull. She had decreased range of motion of the right hip and tenderness over the right buttocks. Her hemoglobin/hematocrit was decreased and her sedimentation rate and C-reactive protein were increased. Plain radiograph (Fig. 1) and ultrasound of the hip were normal. An ultrasound of the skull showed a noncompressible/not fluctuant hypoechoic mass abutting the calvarium that caused significant irregularity of the adjacent calvarium border. Brain MRI (Figs. 2 and 3) was performed with and without gadolinium contrast and showed metastasis causing parietal skull...
protrusion and compression of the right hemispheric sulci and lateral ventricle with subfalcine herniation, resulting from a large right-sided lesion.

MRI of the lumbar spine (Fig. 4) revealed a large left adrenal lesion and multiple lesions throughout the lumbar spine and bilateral iliac bones. MRI of the right hip (Fig. 5) showed diffuse marrow replacement with numerous metastases throughout the lumbar spine, pelvis, and femurs, consistent with neuroblastoma metastases. The patient was admitted to the hospital and other than a mild right eye esophoria that evolved on the
system, specifically neural crest cells [1]. It can arise from any sympathetic nerve ganglion, but it usually occurs in the abdomen, and often from the adrenal gland [2]. The most common areas of metastasis for this tumor type are bones, bone marrow, and liver [3]. While bone and central nervous system (CNS) are common sites of metastatic neuroblastoma [4], as was found in our patient, it is unusual for the presentation to be a limp or have a skull protrusion. Unfortunately, neuroblastoma has no classical symptomatology to raise a clinician’s suspicion. Original presentation of neuroblastoma can range from signs of spinal cord compression, to a generalized rash, or in the case of our patient, joint pain [3]. Our patient was a female but when primary tumor site is stratified on the basis of sex, 2-fold more adrenal tumors occur in boys than girls with no known clear reason for these differences [5].

Additionally, our patient was 6 years old, well above the median age of diagnosis, 19 months—in context, neuroblastomas accounts for 6% of all cancers until age 14 and is the most common cancer found in children under 5 years [3,6–7]. While overall outcomes of patients with neuroblastomas are highly dependent on prompt diagnosis [1] our patient has had the following outcome. She was initially treated with 5 cycles of chemotherapy and subsequent primary tumor resection. Due to continued tumor burden, she had a further 2 cycles of chemotherapy. She underwent 2 autologous stem cell transplants with good response. She also received 4 rounds of maintenance immunotherapy with IL-2 and dinutuximab [8]. Depending on the grade of the neuroblastoma, mortality rates can exceed 90% [9], with this in mind, our patient has done well. She currently has no evidence of disease on her post-treatment evaluations.

Discussion

Neuroblastoma is not usually high on a clinician’s differential for a child’s gait dysfunction and right hip pain. Neuroblastoma is a pediatric malignancy of the sympathetic nervous
Fig. 6 – Histological Images of Bone Marrow. a) Histologic section of bone marrow, demonstrating diffuse distribution of neuroblastoma cells. Hematoxylin and eosin stain, 40x magnification. b) Immunohistochemical staining of paraffin-embedded bone marrow sections for synaptophysin, confirming neuroendocrine differentiation of the bone marrow cells consistent with neuroblastoma, 10x magnification. c) Immunohistochemical staining of paraffin-embedded bone marrow sections for chromogranin, confirming neuroendocrine differentiation of the bone marrow cells consistent with neuroblastoma, 40x magnification. d) Immunohistochemical staining of paraffin-embedded bone marrow sections for CD56 (Neural cell adhesion molecule), confirming neuroendocrine differentiation of the bone marrow cells consistent with neuroblastoma, 10x magnification.
REFERENCES

[1] Davidoff AM. Neuroblastoma. Semin Pediatr Surg 2012;21(1):2–14. doi:10.1053/j.sempedsurg.

[2] Brodeur GM, Hogarty MD, Bagatell R, Mosse YP, Maris JM. Neuroblastoma. Principles and practice of pediatric oncology. 7th ed. Philadelphia PA: Lippincott Williams & Wilkins; 2016. p. 772–92.

[3] Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther 2017;17(4):369–86.

[4] DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21(3):181–9.

[5] Hale G, Gula MJ, Blatt J. Impact of gender on the natural history of neuroblastoma. Pediatr Hematol Oncol 1994;11(1):91–7.

[6] Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203–16.

[7] American Cancer Society. Cancer Facts & Figures 2018. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018 [Accessed August 6, 2018]

[8] Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363(14):1324–34.

[9] Ries L, Smith M, Gurney J, et al. Cancer incidence and survival among children and adolescents: United States SEER Program1975–1995. BethesdaMD: National Cancer Institute, SEER Program; 1999. NIH Pub p. 99–4649.